Phenerex50 mg/2 ml

Phenerex 50 mg/2 ml is a first-generation phenothiazine antihistamine with antiemetic and sedative properties. It is FDA-approved and used for the following indications:

• Allergic conditions: Symptomatic treatment of allergic conditions such as perennial and seasonal allergic rhinitis, allergic conjunctivitis, urticaria, and angioedema; also used as adjunctive therapy in anaphylaxis after acute symptoms have been controlled.
• Nausea and vomiting: Prevention and control of nausea and vomiting associated with various conditions, including postoperative nausea and vomiting.
• Motion sickness: Prevention and treatment of motion sickness.
• Sedation: Preoperative, postoperative, and obstetric sedation; sedation and relief of apprehension in adults and pediatric patients (2 years and older), and to provide light sedation for surgical or diagnostic procedures.
• Adjunct to analgesics: Used with reduced doses of analgesics for control of postoperative pain, as it potentiates the effect of analgesics when used adjunctively.

In Bangladesh, Phenerex 50 mg/2 ml is also commonly used off-label for short-term relief of cough associated with allergic conditions, as part of combination cough preparations, and as a nighttime sedative-antihistamine; such off-label use should be guided by a physician.

Each tablet/formulation of Phenerex 50 mg/2 ml contains Phenerex 50 mg/2 ml as the active ingredient. It is available in Bangladesh as oral tablets (10 mg and 25 mg), oral syrup/solution (5 mg/5 mL), and injection (25 mg/mL and 50 mg/2 mL ampoules). Strength and available excipients may vary by brand and manufacturer; refer to the specific product packaging for exact composition.

Phenerex 50 mg/2 ml is a phenothiazine derivative that acts primarily as a first-generation (sedating) H1-antihistamine, with additional antiemetic, anticholinergic, and sedative properties. It has been used clinically for decades for allergic symptoms, nausea and vomiting, motion sickness, and as a sedative in surgical and obstetric settings. Phenerex 50 mg/2 ml is available as tablets, oral syrup, suppositories, and injectable solution, and is marketed in Bangladesh under multiple brand names in these dosage forms.

Phenerex 50 mg/2 ml belongs to the phenothiazine class of drugs and is classified as a first-generation (sedating) H1-antihistamine with antiemetic and antipsychotic-related pharmacologic properties.

Phenerex 50 mg/2 ml competitively antagonizes histamine at peripheral H1-receptors, which accounts for its antihistaminic and antiallergic effects. As a phenothiazine, it also blocks central dopaminergic receptors in the chemoreceptor trigger zone, giving it antiemetic activity, and it has significant anticholinergic (antimuscarinic) and alpha-adrenergic blocking activity, which contributes to its sedative effects and side-effect profile.

After oral administration, sedative effects typically begin within 20 minutes and last 4-6 hours (occasionally up to 12 hours). Phenerex 50 mg/2 ml is extensively metabolized in the liver, primarily to promethazine sulfoxide and N-demethylpromethazine, and is excreted mainly via the kidneys and bile.

Phenerex 50 mg/2 ml tablets and syrup may be taken with or without food; taking with food may reduce stomach upset. Injectable Phenerex 50 mg/2 ml should be administered by deep intramuscular injection or, when clinically indicated, by slow intravenous injection through a running IV line at the lowest possible concentration; it must never be given subcutaneously. Suppositories are inserted rectally as directed by a physician.

Phenerex 50 mg/2 ml has clinically significant interactions with the following:

• CNS depressants (opioids, benzodiazepines, barbiturates, general anesthetics, alcohol): Additive sedation and risk of severe respiratory depression; concurrent use should be avoided or doses reduced under medical supervision.
• Monoamine oxidase inhibitors (MAOIs): May prolong and intensify the anticholinergic and CNS-depressant effects of Phenerex 50 mg/2 ml; concurrent use is contraindicated (see Contraindications).
• Anticholinergic drugs (tricyclic antidepressants, other antihistamines): Additive anticholinergic effects (dry mouth, urinary retention, constipation, blurred vision).
• Epinephrine: Due to alpha-adrenergic blocking activity, Phenerex 50 mg/2 ml may reverse the pressor effect of epinephrine; if a vasopressor is needed, an agent without significant alpha-blockade reversal risk should be selected.

Phenerex 50 mg/2 ml may also interfere with certain diagnostic tests, including urine pregnancy tests and skin allergen testing (which should be avoided within 72 hours of stopping treatment).

Common side effects of Phenerex 50 mg/2 ml include:

• Drowsiness and sedation (very common, dose-related)
• Dizziness, confusion, disorientation (especially in elderly patients)
• Dry mouth, blurred vision, constipation, urinary retention (anticholinergic effects)
• Photosensitivity (increased sun sensitivity)

Serious but less common adverse effects include:

• Respiratory depression, which can be fatal, particularly in young children and in combination with other CNS depressants (boxed warning).
• Severe tissue injury, including gangrene, with inadvertent intra-arterial injection or perivascular extravasation of the injectable form (boxed warning).
• Neuroleptic malignant syndrome (rare): high fever, severe muscle rigidity, altered mental status, and autonomic instability - a medical emergency.
• Extrapyramidal symptoms (abnormal movements, muscle stiffness).
• Blood dyscrasias (leukopenia, agranulocytosis) - rare.
• Cardiac arrhythmias and QT prolongation - rare.
• Lowered seizure threshold in patients with seizure disorders.

Patients should seek prompt medical attention for difficulty breathing, unusual muscle stiffness, high fever, or signs of an allergic reaction while taking Phenerex 50 mg/2 ml.

Pregnancy: Phenerex 50 mg/2 ml should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, and only under medical supervision. Use should be avoided during the two weeks before delivery when possible, as it may cause increased or decreased motor activity and neonatal irritability in the newborn. High doses used near delivery have been associated with severe neurological signs, including extrapyramidal effects, in the neonate.

Lactation: Phenerex 50 mg/2 ml is excreted in breast milk. Because of the potential for sedation, respiratory effects, or other adverse effects in the nursing infant, it should be used with caution during breastfeeding, and only if clearly needed, after consulting a physician. Antihistamines may also suppress lactation, particularly when combined with other agents.

Boxed Warning: Phenerex 50 mg/2 ml is contraindicated in children under 2 years of age because of the potential for fatal respiratory depression; caution is required when used in children 2 years of age and older, and the lowest effective dose should be used. The injectable form carries a boxed warning for severe tissue injury, including gangrene, following inadvertent intra-arterial injection, perivascular extravasation, or subcutaneous injection; it should be given by deep intramuscular injection, or cautiously by slow intravenous injection into a running IV line, and never subcutaneously.

• Sedation and CNS effects: Phenerex 50 mg/2 ml causes significant drowsiness; patients should avoid driving, operating heavy machinery, or performing other hazardous tasks until they know how it affects them, and should avoid alcohol and other CNS depressants.
• Respiratory disease: Use with caution in patients with compromised respiratory function, such as severe asthma or COPD, and avoid in acute lower respiratory tract symptoms including asthma.
• Seizure disorders: May lower the seizure threshold; use with caution in patients with a history of seizures.
• Narrow-angle glaucoma: Anticholinergic effects may worsen narrow-angle glaucoma; use with caution.
• Elderly patients: More susceptible to hypotension, sedation, confusion, and anticholinergic effects; use the lowest effective dose.
• Bone marrow suppression: Rare cases of blood dyscrasias have been reported; monitor for signs of infection or unusual bleeding/bruising.
• Reye's syndrome: Phenerex 50 mg/2 ml should be used with caution in children and teenagers with symptoms suggestive of Reye's syndrome, as it may mask symptoms such as persistent vomiting.

Overdose of Phenerex 50 mg/2 ml may cause CNS depression (ranging from drowsiness to deep sedation and coma), respiratory depression, hypotension, and in some cases CNS stimulation (particularly in children), including agitation, hallucinations, and seizures. Cardiac arrhythmias, anticholinergic effects, and extrapyramidal symptoms may also occur.

In case of suspected overdose, seek immediate medical attention or contact a poison control center/emergency services right away. Treatment is supportive and should be provided at a medical facility; there is no specific antidote. Do not attempt to manage a suspected overdose at home.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children. Do not use after the expiry date printed on the pack.

Pediatric use: Phenerex 50 mg/2 ml is contraindicated in children under 2 years of age due to the risk of fatal respiratory depression. In children 2 years of age and older, it should be used with caution at the lowest effective dose, and avoided in combination with other drugs that have respiratory depressant effects.

Elderly patients: Older adults are more sensitive to the sedative, hypotensive, and anticholinergic effects of Phenerex 50 mg/2 ml; a lower starting dose is generally recommended, with careful monitoring.

Hepatic impairment: Since Phenerex 50 mg/2 ml is extensively metabolized by the liver, it should be used with caution and at reduced doses in patients with hepatic impairment.

Renal impairment: No well-established dose adjustment is defined; use with caution and clinical monitoring in patients with significant renal impairment.

Duration of treatment with Phenerex 50 mg/2 ml depends on the indication and should be determined by the prescribing physician. For symptomatic relief of allergy, cough, or nausea, treatment is generally short-term (a few days, not exceeding about 10 days without medical reassessment). For sedation or motion sickness, it is typically used on an as-needed, short-term basis. Long-term or repeated use should be periodically reviewed by a physician.

Phenerex 50 mg/2 ml belongs to the following drug classes: Phenothiazine derivative; first-generation (sedating) H1-antihistamine; antiemetic.

Phenerex 50 mg/2 ml works by competitively blocking histamine H1-receptors (antihistaminic effect), blocking dopamine D2-receptors in the brainstem chemoreceptor trigger zone (antiemetic effect), and exerting central anticholinergic and antidopaminergic activity that produces sedation.

C

Phenerex 50 mg/2 ml is contraindicated in children younger than 2 years of age because of the risk of fatal respiratory depression. In children 2 years of age and older, it may be used for allergy, nausea/vomiting, motion sickness, or sedation, but only at the lowest effective dose and with caution, avoiding concomitant use with other respiratory-depressant medications. Safety and efficacy for chronic or unsupervised long-term use in children have not been established, and parents/caregivers should follow a physician's dosing instructions precisely.